Jaguar Health Inc ( JAGX ) shares are trading lower by 10% to $1.08 during Tuesday’s session after the company reported worse-than-expected second-quarter results.

What Happened?

Jaguar Health ( JAGX ) posted a loss of $4.04 per share, which came in worse than the analyst consensus estimate of a loss of $1.11 per share. ]

The company reported quarterly sales of $2.72 million, falling short of the analyst consensus estimate of $3.94 million by 31%. However, this figure reflects a slight increase of 1.6% from the $2.68 million in sales reported in the same quarter of the previous year.

The company's Mytesi prescription volume rose by 5.2% from first-quarter 2024, though it saw a slight year-over-year decline. Financially, Jaguar reduced its net loss by $2.6 million to $9.5 million compared to second-quarter 2023.

Operating losses decreased by $0.9 million, and R&D expenses fell by $0.6 million due to the winding down of its OnTarget clinical trial. The company meanwhile plans a commercial launch of its FDA-approved Gelclair in October 2024 and continues to develop treatments for rare diseases.

Read Also: Starbucks Appoints Chipotle Mexican Grill Veteran As New CEO, Stock Soars

Should I Sell My JAGX Stock?

Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.

Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.

Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Jaguar Health ( JAGX ) stock currently has an RSI of 60.97, indicating neutral conditions.

For analysis tools, charting data and access to exclusive stock news, check out Benzinga PRO. Try it for free.

JAGX has a 52-week high of $35.34 and a 52-week low of $1.03.